P1.12-01 Lung Cancer Screening in the COVID-19 Era: Understanding Program-Level Impact

Abstract

Lung Cancer Screening (LCS) via Low Dose Computed Tomography (LDCT) reduces lung cancer mortality, yet utilization has remained low even before the onset of the COVID-19 pandemic and the resulting disruption to screening (Aberle et al., 2011; de Koning et al., 2020; Jemal, 2017). The impact of COVID-19 on specific LCS program components and how this has led to differences in LCS uptake is unknown. Understanding program-level barriers experienced in the context of COVID-19 will help guide resource allocation and inform optimization of LCS in the future.